Precision BioSciences Inc
PBS0
Company Profile
Business description
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Contact
302 East Pettigrew Street
Dibrell Building, Suite A-100
DurhamNC27701
USAT: +1 919 314-5512
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
67
Stocks News & Analysis
stocks
The ultimate investing hack: dividend growth stocks
Finding companies built for lasting dividend growth.
stocks
Is the data centre party over for Goodman?
Global spending spree on data centres could mean a declining return on invested capital.
stocks
Is AUB an opportunity after shares plunge 17%?
After a takeover bid was withdrawn shares dropped to below the pre-bid price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,894.20 | 5.90 | 0.07% |
| CAC 40 | 8,083.54 | 8.93 | 0.11% |
| DAX 40 | 23,771.24 | 60.38 | 0.25% |
| Dow JONES (US) | 47,474.46 | 185.13 | 0.39% |
| FTSE 100 | 9,692.36 | 9.44 | -0.10% |
| HKSE | 25,760.73 | 334.32 | -1.28% |
| NASDAQ | 23,413.67 | 137.75 | 0.59% |
| Nikkei 225 | 49,864.68 | 561.23 | 1.14% |
| NZX 50 Index | 13,582.54 | 79.77 | 0.59% |
| S&P 500 | 6,829.37 | 16.74 | 0.25% |
| S&P/ASX 200 | 8,595.20 | 4.90 | 0.06% |
| SSE Composite Index | 3,878.00 | 19.71 | -0.51% |